This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Dexcom (DXCM) Gets a Buy from Wells Fargo

Tipranks - Tipranks - Wed Jun 10, 4:28AM CDT

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Dexcom yesterday and set a price target of $85.00. The company’s shares closed yesterday at $76.62.

Introducing TipRanks MCP for Agents

According to TipRanks, Biegelsen is a 3-star analyst with an average return of 1.2% and a 48.30% success rate. Biegelsen covers the Healthcare sector, focusing on stocks such as Abbott Laboratories, Boston Scientific, and Dexcom.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Dexcom with a $81.21 average price target, which is a 5.99% upside from current levels. In a report released yesterday, Raymond James also maintained a Buy rating on the stock with a $91.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Based on Dexcom’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $1.19 billion and a net profit of $199.5 million. In comparison, last year the company earned a revenue of $1.04 billion and had a net profit of $105.4 million

Read More on DXCM:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).